StockMarketWire.com - Diurnal Group said it had successfully completed patient enrollment for its European pivotal clinical trial of Chronocort, a treatment for congenital adrenal hyperplasia in adults.

The Phase III trial was an open label study in which adult patients with CAH, currently treated with a single or combination of generic steroids, were randomised to either receive Chronocort on a twice daily 'toothbrush' regimen or continue on their standard-of-care regimen.

Headline data from the trial was expected in the third quarter and, if positive, could lead to potential market authorisation in Europe in 2020, Duirnal said.


At 2:02pm: [LON:DNL] Diurnal Group Plc share price was +1p at 173.5p



Story provided by StockMarketWire.com